Ipsen CEO to leave post to run gene therapy startup

David Meek, the CEO of biopharmaceutical company Ipsen, will resign from his post Dec. 31 to lead a new gene therapy startup, FerGene, according to EndPoints News

Advertisement

FerGene was launched in November by Ferring Pharmaceuticals and Blackstone Life Sciences. He will take over as CEO on Jan. 14.

The board of Ipsen has named Aymeric Le Chatelier, currently CFO, as interim CEO to replace Mr. Meek until a permanent CEO is found. 

“It has been my honor to work with the great team at Ipsen,” Mr. Meek said. “I am proud of the accomplishments we have achieved together to be one of the fastest-growing companies in our industry.”

More articles on pharmacy:
Humana to buy hospice pharmacy Enclara Healthcare
Kite Pharma ordered to pay Juno Therapeutics $752M in CAR-T drug infringement case
Walgreens is Dow’s worst-performing stock of 2019

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

The Performance Gap Your Pharmacy Training Metrics Can’t See

Monday, August 10
12:00 PM - 1:00 PM CDT

Presenters: Michael Alexander, AudirieDr. Tina Moen, PharmD, Colibri Healthcare

Advertisement

Next Up in Pharmacy

Advertisement

Comments are closed.